Vera Net Income From Continuing Ops from 2010 to 2026
| VERA Stock | USD 41.76 0.39 0.93% |
Net Loss | First Reported 2020-03-31 | Previous Quarter -76.5 M | Current Value -80.3 M | Quarterly Volatility 43.3 M |
Check Vera Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vera Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 800, Net Interest Income of 15.8 M or Interest Income of 25 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.78. Vera financial statements analysis is a perfect complement when working with Vera Therapeutics Valuation or Volatility modules.
Vera | Net Income From Continuing Ops | Build AI portfolio with Vera Stock |
Analyzing Vera Therapeutics's Net Income From Continuing Ops over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income From Continuing Ops has evolved provides context for assessing Vera Therapeutics's current valuation and future prospects.
Latest Vera Therapeutics' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Vera Therapeutics over the last few years. It is Vera Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vera Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Vera Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (37,496,926) | |
| Geometric Mean | 27,150,369 | |
| Coefficient Of Variation | (161.58) | |
| Mean Deviation | 45,631,778 | |
| Median | (11,854,000) | |
| Standard Deviation | 60,588,173 | |
| Sample Variance | 3670.9T | |
| Range | 241.2M | |
| R-Value | (0.58) | |
| Mean Square Error | 2579.6T | |
| R-Squared | 0.34 | |
| Significance | 0.01 | |
| Slope | (7,008,632) | |
| Total Sum of Squares | 58734.8T |
Vera Net Income From Continuing Ops History
About Vera Therapeutics Financial Statements
Vera Therapeutics stakeholders use historical fundamental indicators, such as Vera Therapeutics' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Vera Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Vera Therapeutics' assets and liabilities are reflected in the revenues and expenses on Vera Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Vera Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -136.9 M | -130.1 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Vera Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vera Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vera Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vera Therapeutics Stock:Check out the analysis of Vera Therapeutics Correlation against competitors. For information on how to trade Vera Stock refer to our How to Trade Vera Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vera Therapeutics. If investors know Vera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Vera Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Vera Therapeutics requires distinguishing between market price and book value, where the latter reflects Vera's accounting equity. The concept of intrinsic value - what Vera Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Vera Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Vera Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vera Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Vera Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.